138 results about "Surface protein" patented technology

The invention provides a polypeptide, and the sequence of the polypeptide is AEDVGDVAFVKNDT. The polypeptide provided by the invention can inhibit the human respiratory syncytial virus surface protein F so as to inhibit the fusion of the human respiratory syncytial virus surface protein F and a host cell membrane. The invention also provides the sheep colostrum. The sheep colostrum comprises the polypeptide with the antiviral function, so that the sheep colostrum is helpful for old people with relatively weak resistance to resist infection of human respiratory syncytial viruses and promotes repair of respiratory mucosa. The invention also provides a preparation method of the sheep colostrum. The preparation method is simple and can be used for industrial production. The invention also provides a preparation method of the polypeptide.

The invention discloses a method for separating and detecting new intestinal bacterial exovesicles, which comprises the following steps: (1) carrying out metabolism labeling on microorganisms to be researched by an azido-modified hydrochloric acid D-type amino acid metabolism marker, so that the new intestinal bacterial exovesicles carry azido groups; (2) separating and extracting the bacterial exovesicles from a sample containing the bacterial exovesicles; (3) adding a capture connector capable of reacting with an azide group into the extracted bacterial outer vesicles; and (4) separating, capturing and detecting the bacterial outer vesicles obtained in the step (3) by adopting a micro-fluidic chip, wherein the obtained bacterial outer vesicles are newborn bacterial outer vesicles. The method disclosed by the invention can selectively capture the newborn bacterial exovesicles from the sample under the condition of not influencing surface protein expression of the bacterial exovesicles so as to carry out downstream analysis on the newborn bacterial exovesicles of the intestinal flora.

The application discloses a kind of fowl secretory bacterium surface proteins and its screening method and application, belong to biotechnology field.The application can be soluble high-efficiency expression in escherichia coli by screening protective antigen from fowl secretory bacterium heparin binding protein, combined with antigen prediction, soluble analysis and structure-oriented protein design, successfully obtained protein A0A3Q9GGY1, A0A3S9QKJ0 and six-site mutant PLO that can be soluble high-efficiency expression in escherichia coli, has good immunoprotective efficiency, and has accumulated experience for the screening and design of high-yield antigen, and has laid a foundation for the research and development of fowl secretory bacterium vaccine.

Providing nucleic acid constructs that enhance antigen-specific immune responses against enveloped viruses. [Solution] A nucleic acid construct comprising a polynucleotide encoding a SNARE protein selected from the group consisting of VAMP7, STX7, GOSR1, and SEC22B, and a polynucleotide encoding a surface protein antigen of an enveloped virus.

The application belongs to the technical field of biological medicine, and particularly discloses application of Lactobacillus delbrueckii surface protein DUF4430 in preparation of a medicine for improving symptoms of ulcerative colitis, and preventing and / or treating ulcerative colitis. The application provides a new use of the Lactobacillus delbrueckii surface protein DUF4430, including application in preparation of a medicine for improving symptoms of ulcerative colitis, and preventing and / or treating ulcerative colitis. Animal experiments show that the Lactobacillus delbrueckii surface protein DUF4430 can relieve DSS-induced ulcerative colitis in mice, improve weight loss, shorten colon length, and reduce colon mucosal injury, reduce the content of pro-inflammatory cytokines (such as IL-1β and IL-6) in the colon, increase the content of anti-inflammatory cytokines (such as IL-10), reduce the proportion of pro-inflammatory macrophages in the spleen and colon, and inhibit the pro-inflammatory phenotype of macrophages, and therefore can be used for preparing a medicine for improving symptoms of ulcerative colitis, and preventing and treating ulcerative colitis.

A hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

The invention discloses a preparation method of a Ca (OH) 2 activated fish scale-based adsorbent, and relates to the technical field of functional materials. Comprising the following steps: 1, pretreating fish scales: carrying out acid treatment on the cleaned and dried fish scales to obtain fish scales without surface protein, carrying out alkali treatment on the fish scales to obtain fish scale slurry, drying the fish scale slurry to obtain fish scale powder, and 2, dissolving the fish scale powder and Ca (OH) 2 in water according to a mass ratio of the fish scale powder to Ca (OH) 2 of 1: 3-3: 1, adding pyrrole, fully mixing, and carrying out drying to obtain the fish scale powder. The mass volume ratio of the fish scale powder to pyrrole is (1: 8)-(1: 2), and the volume ratio of pyrrole to the potassium persulfate aqueous solution is (3: 20)-(3: 5), and step 3, carrying out suction filtration and solid-liquid separation on the composite product, repeatedly washing to be neutral, and drying to obtain the polypyrrole composite Ca (OH) 2 activated fish scale-based adsorbent.

Provided are an antigen-binding protein neutralizing respiratory syncytial virus (RSV) and a use thereof. The antigen-binding protein comprises a single-domain antibody containing CDR1, CDR2, and CDR3 antigen complementarity-determining regions, and has the function of exerting virus-neutralizing activity by recognizing and binding to RSV surface proteins. The antigen-binding protein can prevent or treat diseases caused by RSV infection.

A cell exosome, which contains, on the membrane surface thereof, one or more phospholipids of a high-fluidity liposome and a surface protein of a cancer cell.

The invention relates to an application of a cerium oxide nano-material in a vaccine adjuvant and / or a vaccine inactivator, in particular to a vaccine, when the cerium oxide nano-material is the vaccine adjuvant, the vaccine comprises the vaccine adjuvant and an immunogen; or when the cerium oxide nano material is a vaccine inactivating agent, the vaccine is a composite vaccine, the composite vaccine comprises the vaccine inactivating agent and a virus, and the virus is embedded in the cerium oxide nano material; the preparation method of the composite vaccine comprises the step of mineralizing and inactivating viruses by using a vaccine inactivator, wherein the vaccine inactivator is cerium salt. The cerium oxide can be used as a vaccine adjuvant and also can be used as a virus inactivator. The maturation of dendritic cells and macrophages can be promoted by means of regulating the level of active oxygen in immune cells and the like, and the antigen presentation efficiency is improved, so that the vaccine-induced body fluid and cellular immune response is enhanced; meanwhile, cerium salt can directly act on virus surface protein for mineralization, efficient and safe virus inactivation is achieved, and preparation of inactivated vaccines is facilitated.

The technology proposed herein concerns a vaccine formulation comprising a) an antigen comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of the N-terminal region of a first group B Streptococcus surface protein, and b) a buffer having a pH of 6 to 8 and comprising: a. aluminum hydroxide gel particles, and b. a buffer system comprising: i. 1-3 mM phosphate and 100-200 mM NaCl, or ii. 5-15 mM histidine and 200-400 mM sorbitol. The technology proposed herein further concerns a method of producing a vaccine formulation as well as a vaccine formulation for use in a method of reducing, preventing and / or treating a GBS infection.

The application discloses a kind of biological immobilized enzyme based on yeast surface display technology and the application of synthesis 2-phenylethanol, using yeast surface display technology, for the first time with Saccharomyces cerevisiae surface protein a-lectin as anchor protein, the key enzyme (transaminase, decarboxylase, ethanol dehydrogenase) involved in 2-PE producing Ehrlich pathway in Saccharomyces cerevisiae is separately or jointly carried out biological fixation, enhance substrate channel effect and proximity effect, in vitro one-step catalysis L-phenylalanine synthesis 2-PE, provide yield.The method for fixing multiple enzymes of Ehrlich pathway in the application can be used to reconfigure the biosynthesis pathway of other natural products in vitro, to provide feasible scheme for the rational design of cell factory.

This invention discloses a kit for in vitro quantitative detection of hepatitis B virus large surface protein (LHBS). This kit includes multiple monoclonal antibodies, each with its own binding specificity to specific regions of LHBS, thereby improving the sensitivity and dynamic range of LHBS detection in biological samples. Secondly, this invention also provides a set of biological markers targeting specific regions of LHBS, and the monoclonal antibodies can specifically identify this set of biomarkers, enabling non-invasive analysis of HBV infection stages and liver cancer prognosis in biological samples. Furthermore, this invention also provides a set of monoclonal antibodies that, by detecting biomarkers in desired subjects, can predict, diagnose, or treat chronic liver disease.

The invention discloses arcanobacterium pyogenes surface protein as well as a screening method and application thereof, and belongs to the technical field of biology. According to the invention, a protective antigen which can be soluble and efficiently expressed in escherichia coli is screened from arcanobacterium pyogenes heparin binding protein, and antigen prediction, solubility analysis and structure-oriented protein design are combined; proteins A0A3Q9GGY1, A0A3S9QKJ0 and a six-site mutant PLO which can be soluble and efficiently expressed in escherichia coli and have good immune protection efficacy are successfully obtained, experience is accumulated for screening and design of high-yield antigens, and a foundation is laid for research and development of arcanobacterium pyogenes vaccines.

This invention discloses a single-chain antibody against the S1 protein on the surface of SARS-CoV-2, comprising a heavy chain sequence and a light chain sequence. The invention also discloses a gene encoding the above sequence, a recombinant vector containing the above gene, a host cell containing the above vector, a biological agent containing the above antibody, and the application of the above antibody against SARS-CoV-2. This effectively solves the problem of a lack of highly potent antibodies against SARS-CoV-2.

Disclosed are a modified nucleic acid aptamer-paclitaxel conjugate, a preparation method therefor, and use thereof. The modified nucleic acid aptamer-paclitaxel conjugate comprises paclitaxel, a succinic acid linker, and an AS1411 aptamer modified with a G4 ligand. In the modified nucleic acid aptamer-paclitaxel conjugate, a nucleic acid aptamer and paclitaxel are coupled by means of a linking bond, and then a target conjugate is obtained by modifying the structure of the nucleic acid aptamer with a G-quadruplex stabilizer using a chemical method. The conjugate has better tumor targeting properties and ultimately specifically targets tumor cell surface proteins, thereby exhibiting anti-cancer activity for the treatment of cancer.

The application discloses a composite hydrogel based on urethral stem cell membrane sheet ECM and exosomes and a preparation method and application thereof, and relates to the technical field of tissue engineering, and in particular relates to a soluble ECM protein solution obtained by dissolving and enzymatically hydrolyzing urethral stem cell membrane sheet decellularized matrix (ECM) powder and mixing the soluble ECM protein solution with exosomes in a mass ratio of 3:1-10:1, and performing temperature-sensitive crosslinking in DMEM at pH 7.0 and 36-38 DEG C to form a hydrogel. The composite hydrogel based on urethral stem cell membrane sheet decellularized matrix (ECM) and exosomes integrates the cell activity of the urethral stem cell membrane sheet, the structural support of the decellularized matrix (ECM) and the signal regulation of the exosomes, constructs a three-level functional system, forms a synergistic repair effect, and is helpful to promoting angiogenesis in the urethra. Through covalent coupling of the decellularized matrix (ECM) fiber network and the surface protein of the exosomes, the intelligent release of the exosomes in an inflammatory environment is realized, and the composite hydrogel is used for urethral repair and angiogenesis promotion.

The invention relates to a microfluidic device. Said device has at least one magnetic marker, which is designed to bind to surface proteins of cells (30, 31), at least one mixing region, which is designed to bring the at least one magnetic marker into contact with the cells (30, 31), and at least one separating region (14), into which the cells (30, 31) can be introduced and which has at least one magnet (15), preferably on an upper side (16). A method for separating cells by means of the microfluidic device comprises bringing cells (30, 31) into contact with at least one magnetic marker in the mixing region, sedimenting the cells (30, 31) in the separating region (14), applying a magnetic field in the separating region (14), and discharging cells (31) marked with the marker from the separating region by means of a fluid flow (61).

The invention relates to the field of food processing, and particularly discloses a method for improving the quality of frozen flour products by using modified rice starch. The improved frozen dough is prepared from, by weight, 100 parts of flour mixture, 0.8-1 part of salt, 1.5-2 parts of yeast, 9-10 parts of sugar, 4-6 parts of butter and 50-55 parts of water, and the flour mixture is prepared from rice starch and wheat flour which are subjected to starch particle surface protein removal and multi-stage power ultrasonic synergistic modification according to the mass ratio of 0.2: 9.8. The rice starch which is used for removing protein on the surfaces of starch particles and is subjected to multi-stage power ultrasonic synergistic modification is added, so that the nutritional value of the frozen dough is effectively improved, the specific volume and the tissue structure of flour products are improved, and meanwhile, the taste can be enhanced.

The present invention relates to a recombinant protein comprising one or more fragments of the surface protein A (PspA) of the pneumococcal, and an adenylate cyclase (CyaA) from the genus Bordetella, in particular Bordetella pertussis, in which the fragments of the PspA are selected from the group consisting of clades 1 to 4, or a combination of two or more thereof. Furthermore, the present invention relates to an expression cassette comprising a DNA sequence encoding said recombinant protein, in particular a DNA sequence selected from the nucleotide sequences represented by SEQ ID NO: 12 to 18 and a degenerate sequence thereof, which respectively encode the recombinant protein represented by SEQ ID NO: 5 to 11. In addition, immunogenic compositions comprising the recombinant protein or the expression cassette and further pharmaceutically acceptable carriers and / or adjuvants are disclosed. Finally, the present invention relates to the use of said recombinant protein, said expression cassette or said immunogenic composition for the preparation of a vaccine for the prevention of infection by Streptococcus pneumoniae wherein said vaccine provides broad spectrum protection against different pneumococcal isolates regardless of serotypes.

Provided are innovative compositions for tethering blocking an inactivating of airborne respiratory infectious viruses. The compositions comprise bispecific proteins with two different antigen binding regions (ABR), which are typically configured as immunoglobulin “single variable domains” (ISV). A first ISV binds to a surface protein found on an airborne infectious virus. A second ISV binds to a mucin protein, e.g. a mucin protein present on ocular, nasopharyngeal, tracheal and / or oral surfaces of a mammal. The two ISV are joined by a polypeptide linker.

The present invention relates to the provision of trifunctional crosslinker compounds comprising (i) a moiety reactive with an amino acid side chain for selective labelling of proteins, (ii) a cleavable linker moiety and (iii) an affinity moiety for the detection, isolation and purification of captured proteins. The invention further relates to uses of the cleavable crosslinking reagents in methods for detecting, labelling, identifying and characterizing proteins and protein interactions in or on the surface of intact cells, cell lysates and / or protein mixtures.

The invention belongs to the technical field of biological medicine, and discloses an enteritis targeted probiotic delivery system and a preparation method and application thereof, the system comprises: i) a recombinant plasmid for coding an anti-inflammatory functional protein, the plasmid comprising an anti-inflammatory peptide fragment, a surface protein modification and an antibiotic switch; ii) Escherichia coli chassis bacteria which are subjected to genetic engineering modification and have the capability of high yield of outer membrane vesicles; and iii) introducing the recombinant plasmid into the escherichia coli chassis bacterium to obtain a recombinant engineering bacterium. The delivery system disclosed by the invention can target intestinal inflammation parts, deliver anti-inflammatory proteins through the outer membrane vesicles, and specifically release anti-inflammatory factors in an inflammation microenvironment, so that intestinal inflammation response is relieved; according to the present invention, the method can achieve the precise targeting on the intestinal inflammation, can effectively control the remote delivery and the continuous secretion of the anti-inflammatory protein in space and time, has advantages of strong targeting property, lasting effect, small side effect and the like, and provides the new strategy for the safe and efficient treatment of the intestinal inflammation diseases.

The application provides application of psoralen in activating NK cells. The psoralen provided by the application is a coumarin component extracted from traditional Chinese medicine psoralea; through in-vitro cell experiment verification, the psoralen can activate NK-92 to secrete IFN-gamma, Granzyme B and Perforion, and activate surface protein NKG2D of NK-92; meanwhile, the psoralen also has the same effect on a cell group containing NK cells; through in-vivo experiment verification, the psoralen helps to improve the total amount of NK cells in the mouse spleen, inhibit tumor growth, and improve the expression amount of IFN-gamma, Granzyme B, Perforion, NKG2D, NKP46 and CD107a in a tumor infiltration environment. In summary, the small-molecule compound psoralen has good effect in activating NK cells.

The invention provides a medical instrument humectant and a preparation method thereof. The medical instrument humectant comprises the following components: 5-10 parts of a first anionic surfactant; 1-4 parts of a zwitterionic surfactant; 1-3 parts of a second anionic surfactant; 2 to 5 parts of a polyol humectant; 0.10 to 0.30 part of a first bacteriostatic agent; 0.1 to 0.4 part of an organic phosphonic acid antirust agent; 1-4 parts of a small molecule polyol humectant; 0.01 to 0.08 part of a second bacteriostatic agent; 0.005 to 0.03 part of protease; and the balance of deionized water. According to the present invention, the inhibition rate of common pathogenic bacteria can be improved, and the antibacterial duration can be prolonged; the anti-rust performance is improved; protein residues on the surface of the instrument are efficiently decomposed, meanwhile, a stable moisturizing film is formed, and synergistic cleaning and moisturizing are achieved; the product stability is improved, and layering and precipitation in the storage process are avoided.

Compositions comprising aptamers capable of specifically binding to a surface protein of Clostridium difficile spore are provided. A method for detecting, enriching, separating, and / or isolating Clostridium difficile spores is provided.

The invention discloses application of desoxyribonucleic acid-poly-L-lysine composite hydrogel in redistribution of endogenous exosomes and treatment of myocardial infarction, and the desoxyribonucleic acid-poly-L-lysine composite hydrogel comprises a DNA (deoxyribonucleic acid) skeleton and poly-L-lysine wrapping the DNA skeleton, the DNA skeleton contains a nucleic acid aptamer targeting exosome surface protein, and the desoxyribonucleic acid-poly-L-lysine composite hydrogel is used for capturing and releasing endogenous exosomes. According to the invention, the injectable desoxyribonucleic acid-poly-L-lysine composite hydrogel is used for treating myocardial infarction, and targeted enrichment and controllable release of endogenous exosomes are realized through the unique molecular design of the desoxyribonucleic acid-poly-L-lysine composite hydrogel; important breakthrough is achieved in the aspects of targeting, controllability, safety, clinical transformation and the like, and a brand new solution is provided for myocardial infarction treatment.

The purpose of the present invention is to provide an immunogenic composition containing a new HBV polypeptide or polynucleotides encoding the polypeptide. The immunogenic composition contains at least one polypeptide selected from among polypeptides a) through c) or polynucleotides encoding the polypeptide, and can be used for treating or preventing HBV infection. a) an HBV surface protein polypeptide including a specific amino acid substitution; b) an HBV polymerase polypeptide including an inactivated reverse transcriptase domain and an inactivated ribonuclease H domain, and including a specific amino acid substitution; and c) an HBV core protein polypeptide including a specific amino acid sequence.

Provided herein are methods for highly multi-plexed detection and quantification of co-localized membrane surface proteins. Provided herein are also methods for determining the likelihood that a subject has a disease or condition, such as cancer.

The present invention relates to self-assembling multimeric protein particles displaying Borrelia antigens, namely an encapsulin protein particle displaying an 'outer surface protein A' (OspA) antigen and a DPS (DNA binding protein from starved cells) protein particle displaying a mutant 'complement regulator-acquiring surface protein 2' (CspZ) antigen for use in the vaccination against Lyme disease, particularly in combination.